CN117624354A - Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof - Google Patents
Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN117624354A CN117624354A CN202311626889.XA CN202311626889A CN117624354A CN 117624354 A CN117624354 A CN 117624354A CN 202311626889 A CN202311626889 A CN 202311626889A CN 117624354 A CN117624354 A CN 117624354A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- tau281
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title claims abstract description 45
- 238000001514 detection method Methods 0.000 claims abstract description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 238000003118 sandwich ELISA Methods 0.000 claims abstract description 11
- 238000003018 immunoassay Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract description 8
- 102000036639 antigens Human genes 0.000 abstract description 8
- 108091007433 antigens Proteins 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 102000013498 tau Proteins Human genes 0.000 description 18
- 108010026424 tau Proteins Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000011161 development Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012089 stop solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004688 microtubule Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 230000006295 S-nitrosylation Effects 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005002 finish coating Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The application belongs to the technical field of immunodetection, and discloses an anti-human acetylated tau281 rabbit monoclonal antibody and application thereof. The anti-human acetylated tau281 rabbit monoclonal antibody provided by the application comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises LCDR1-3, LCDR1 comprises an amino acid sequence shown as SEQ ID NO.3, LCDR2 comprises an amino acid sequence shown as SEQ ID NO.4, and LCDR3 comprises an amino acid sequence shown as SEQ ID NO. 5; the heavy chain variable region comprises HCDR1-3, wherein HCDR1 comprises an amino acid sequence shown as SEQ ID NO.6, HCDR2 comprises an amino acid sequence shown as SEQ ID NO.7, and HCDR3 comprises an amino acid sequence shown as SEQ ID NO. 8. The rabbit monoclonal antibody can be combined with human acetylated tau281 protein with high specificity, and can be applied to double antibody sandwich ELISA for detecting human acetylated tau281 standard antigen, and the detection sensitivity is less than 78pg/ml.
Description
Technical Field
The application relates to the technical field of immunodetection, in particular to an anti-human acetylated tau281 rabbit monoclonal antibody and application thereof.
Background
Alzheimer's disease (Alzheimer disease, AD) is a common neurodegenerative disease, which is a central nervous system degenerative disease, and the clinical inter-subject is progressive decline of memory function, cognitive dysfunction, language and social function, and even personality changes and loss of life ability, etc., which eventually leads to death. Typical histopathological changes are deposition of β -amyloid (aβ) leading to senile plaques, neurofibrillary tangles caused by abnormal phosphorylation of Tau protein, loss of neurons and synapses.
Tau protein is widely present in the nervous system, and is a major component constituting microtubules, and has functions of promoting microtubule assembly and maintaining microtubule stability. In the course of AD onset, microtubule structure changes, the integrity of microtubule structure is destroyed, dissociation of tubulin is promoted, and stability is destroyed. While tau protein bound to microtubules is also altered, neurofibrillary tangles, which are predominantly hyperphosphorylated tau protein, are an important pathological feature of AD, other forms of posttranslational modification of tau protein, such as acetylation, also directly or indirectly regulate the conformation and function of the protein.
In recent years, acetylated tau has been reported to be a blood biomarker for mouse and human traumatic brain injury-induced neurodegeneration. Brain injury induces neuronal tau protein acetylation, driven by non-classical signals, which in a cellular model of AD is associated with S-nitrosylation of GAPDH, which synergistically enhances p300/CBP acetyltransferase activity and inhibits Sirtuinl (Sirtl) deacetylase activity to increase the total amount of acetylation, leading to axonal initial segment degradation and pathological tau localization errors.
Therefore, the concentration of acetylated tau281 can be used as a biomarker for distinguishing AD from non-AD dementia in blood examination, and there is a great need for an anti-human acetylated tau281 rabbit monoclonal antibody and a detection method which can realize high sensitivity, high specificity and high affinity for human acetylated tau 281.
Disclosure of Invention
In order to overcome the technical problems, the application provides an anti-human acetylated tau281 rabbit monoclonal antibody with high sensitivity, strong specificity and high affinity, and application thereof in a double-antibody sandwich ELISA immunodetection kit, and provides auxiliary diagnosis for Alzheimer's disease and senile dementia related to human acetylated tau 281.
In a first aspect, the present application provides a rabbit monoclonal antibody against human acetylated tau281 comprising a light chain variable region and a heavy chain variable region.
The light chain variable region comprises LCDR1-3, wherein LCDR1 comprises an amino acid sequence shown as SEQ ID NO.3, LCDR2 comprises an amino acid sequence shown as SEQ ID NO.4, and LCDR3 comprises a sequence shown as SEQ ID NO. 5;
the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence as shown in SEQ ID NO.6, the HCDR2 comprises an amino acid sequence as shown in SEQ ID NO.7, and the HCDR3 comprises a sequence as shown in SEQ ID NO. 8.
Alternatively, the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.1, VL of 110 amino acids in full length, FR of 26, 17, 36 and 10 amino acids in the 4 domains, LCDR of 8, 3 and 10 amino acids in the 3 domains, LCDR1, LCDR2 and LCDR3 of 27aa-34aa,52aa-54aa and 91aa-100aa, respectively, and the amino acid sequences are: QNVYNGNNR (SEQ ID NO. 3), QAS (SEQ ID NO. 4), AGWASDYTHA (SEQ ID NO. 5).
The heavy chain variable region comprises an amino acid sequence shown as SEQ ID NO.2, wherein the total length of VH is 112 amino acids, the amino acid numbers of 4 structural domains of FR are respectively 24, 17, 37 and 11, the amino acid numbers of 3 structural domains of HCDR are respectively 8, 7 and 8, HCDR1, HCDR2 and HCDR3 are respectively 25aa-32aa,50aa-56aa and 94aa-101aa, and the amino acid sequences are respectively GFSLSNDW (SEQ ID NO. 6), ISHSGTT (SEQ ID NO. 7) and ARHIGGDD (SEQ ID NO. 8).
In a second aspect, the present application also provides an isolated polynucleotide encoding the rabbit monoclonal antibody of the first aspect against human acetylated tau 281.
In a third aspect, the present application also provides a recombinant expression vector comprising a polynucleotide according to the second aspect of the present application.
In a fourth aspect, the present application also provides a host cell comprising the recombinant expression vector of the third aspect, preferably the host cell is a prokaryotic cell or a eukaryotic cell.
In a fifth aspect, the present application also provides an immunoassay product for detecting human acetylated tau281, the immunoassay product comprising a rabbit monoclonal antibody as described in the first aspect of the present application.
Optionally, the immunodetection product is a detection kit, a chip or a detection test paper.
In a sixth aspect, the application also provides the use of the rabbit monoclonal antibody of the first aspect in the preparation of an immunoassay product for detecting human acetylated tau281 protein.
Optionally, the immunodetection product is a detection kit, a chip or a detection test paper.
Optionally, the detection kit is a double-antibody sandwich ELISA detection kit or a chemiluminescent immunoassay kit.
Compared with the prior art, the rabbit monoclonal antibody of the anti-human acetylated tau281 can be high-specific to human acetylated tau281 proteinBind with high affinity, and have affinity constant Ka of 6.7X10 8 L/mol. The rabbit monoclonal antibody for resisting the human acetylated tau281 can also be prepared into an immunodetection kit for detecting the acetylated tau281, and particularly can be applied to a double-antibody sandwich ELISA immunodetection kit, and the detection sensitivity is less than 78pg/ml.
Drawings
FIG. 1 is an electrophoretogram of full-length amplification products of heavy and light chains of the rabbit monoclonal antibody OTIR5D9, M is a DNA molecular weight Marker.
FIG. 2 shows the detection of human acetylated tau281 polypeptides, non-acetylated tau281 polypeptides, human acetylated tau281 full-length proteins and non-phosphorylated full-length tau full-length protein samples by indirect sandwich ELISA, with the ordinate of the OD values detected.
FIG. 3 shows the detection of human acetylated tau281 standard antigen by double antibody sandwich ELISA, the abscissa shows the concentration (ng/ml) of human acetylated tau281 standard antigen and the ordinate shows the OD value of the detection. R of standard curve 2 =0.9904, linear detection range 0-10000pg/mL, deriving the sample concentration calculation formula: y=0.0002x+0.1459.
Detailed Description
The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental procedures, which do not address the specific conditions in the examples below, are generally performed under conventional conditions, those described in the laboratory manual, or those suggested by the manufacturer.
Example 1 preparation of anti-human acetylated tau281 Rabbit monoclonal antibodies
1) Preparation of human acetylated tau281 immunogen
The immunogenic polypeptide is designed according to the 1-441aa sequence of tau protein (NP 005901.2) (2N 4R variant), the polypeptide sequence is 270-300aa, the purity of the polypeptide is over 90 percent, and the purity requirement for preparing monoclonal antibody is met. The polypeptides were synthesized by peptide biochemistry limited in a third party.
2) Immunization of animals
The synthesized human acetylated tau281 polypeptide is emulsified by complete Freund's adjuvant in a volume ratio of 1:1, about 2kg of New Zealand white rabbits are immunized by a subcutaneous injection method, the immunization dose is 800 mug/animal, the immunization is carried out for the second time after two weeks, the incomplete Freund's adjuvant is emulsified in a volume ratio of 1:1, and the immunization dose is 400 mug/animal. Tail blood is taken after two times of immunization, and serum titer is measured by ELISA method gradient dilution; and judging whether to collect PBMCs or continue immunization according to the result by taking OD450 at ELISA titer 128000 as a standard and selecting rabbits with highest antibody titers for collecting the PBMCs.
3) PBMCs separation, specific B cell separation, cloning recombination
Fixing rabbit on operation table, removing hair from heart, sterilizing skin with alcohol, selecting the most obvious heart beat, puncturing with 50ml syringe, injecting blood into syringe after needle, rapidly removing needle after obtaining required blood volume, transferring whole blood in syringe into sterile 50ml tube, mixing with equal amount of PBS, slowly adding dropwise above lymphocyte separating liquid, centrifuging at room temperature 400×g for 30min, and separating liquid level into four layers from top to bottom: the rabbit PBMCs are obtained by carefully sucking the mononuclear cell layer and washing and removing the platelet and lymphocyte separating liquid by PBS.
Antigen-specific B cells were further sorted from rabbit PBMCs for culture, and the supernatant of the cultured B cells was screened for positive clones using antigen-coated ELISA plates. The positive cloned cells are collected, lysed, RNA is extracted and reversely transcribed into cDNA, the natural paired rabbit monoclonal antibody light chain and heavy chain full-length sequences are amplified from the cDNA corresponding to the positive clone, a rabbit monoclonal antibody expression vector is constructed by a cloning recombination method, the sequences are determined by sequencing, and the amplified full-length PCR product results are shown in figure 1.
4) Preparation and purification of monoclonal antibodies
To obtain a plurality of rabbit monoclonal antibodies recognizing human acetylated tau281 proteins, heavy chain and light chain genes of the rabbit monoclonal antibodies are loaded on an expression vector, KEK293 cells are transfected by plasmids, and the recombinant rabbit monoclonal antibodies recognizing human acetylated tau281 proteins are obtained from culture supernatants after 120-144 hours of transfection. Collecting cell suspension, centrifuging to obtain supernatant, and performing antibody purification by affinity chromatography. The concentration of the purified monoclonal antibody was measured by BCA method, and then sub-packaged and lyophilized to give the purified antibody designated rabbit monoclonal antibody otor 5D9.
Example 2 identification of anti-human acetylated tau281 rabbit monoclonal antibody OTIR5D9
1) Specificity identification of Rabbit monoclonal antibodies
Indirect ELSA assay was used. Coating ELISA plate with human acetylated tau281 polypeptide, non-phosphorylated tau281 polypeptide, human acetylated tau281 full-length protein and non-phosphorylated full-length tau protein at concentration of 1 μg/ml overnight at 4deg.C, blocking ELISA plate with PBST containing 1% BSA, adding 10 4 The purified rabbit monoclonal antibody OTIR5D9 subjected to double dilution is reacted for 50min at 37 ℃, PBST is washed for 3 times, HRP-goat anti-rabbit Ig secondary antibody is added for 50min at 37 ℃, PBST is washed for 5 times, TMB is added for color development for 10min, stop solution is added, and A450 is measured by an enzyme-labeled instrument.
FIG. 2 shows that the non-phosphorylated tau281 polypeptide and the non-phosphorylated full-length tau protein react negatively with the rabbit monoclonal antibody OTIR5D9, and OD450 is less than 0.1; the human acetylated tau281 polypeptide and the human acetylated tau281 full-length protein react positively with the OTIR5D9 antibody, and OD450 is larger than 1, which shows that the anti-human acetylated tau281 rabbit monoclonal antibody OTIR5D9 specifically recognizes the threonine (T) phosphorylation site epitope at position 281 in tau protein.
2) Affinity constant determination of rabbit monoclonal antibodies
Affinity constants (Ka) were determined by non-competitive ELISA.
Coating: diluting antigen with carbonate buffer solution to concentration of 1, 0.5, 0.1 and 0.05 mug/mL, respectively coating the antigen with 96-well ELISA plates according to 100 mug/well, and incubating for 24 hours at 4 ℃;
closing: the plates were washed 4 times with PBST, BSA solution was added at 200. Mu.L/well and incubated for 2h at 37 ℃;
adding monoclonal antibody: plates were washed 4 times with PBST, and mab OTIR5D9 was diluted with carbonate buffer at a starting doubling ratio of 100. Mu.g/mL, 100. Mu.L was added to each well and incubated for 2h at 37 ℃;
adding enzyme-labeled secondary antibodies: washing the plate with PBST for 4 times, adding 100 mu L of L10000 times diluted goat anti-rabbit Ig secondary antibody at 37 ℃ into each hole, and standing for 30min;
color development and termination: washing the plate with PBST for 4 times, adding 100 mu L of substrate color development liquid into each hole, and carrying out light-shielding reaction for 15min at 37 ℃; 50. Mu.L of 1.0mol/L H was added to each well 2 SO 4 A stop solution for stopping the reaction;
and (3) detection: the absorbance at a wavelength of 450nm (A450 nm) was measured.
Drawing an S-shaped curve by taking the logarithm of the concentration of the antibody as the abscissa and the OD value as the ordinate, calculating the affinity constant Ka=6.7X10 of the anti-human acetylated tau281 rabbit monoclonal antibody OTIR5D9 8 L/mol。
3) Antibody pairing
To select the optimal combination of coated and detection antibodies, three purified rabbit monoclonal antibodies, OTIR5H6, OTIR1D9 and OTIR5D9, were coated on the ELISA plate, respectively, overnight at 4 ℃. The enzyme label plate is taken out the next day, PBST is washed once, 1% BSA solution is blocked for 2 hours at 37 ℃, and PBST is washed 3 times; 100 μl of human acetylated tau281 full-length protein was added to each well, at a concentration of 20ng/ml, and incubated at 37deg.C for 1 hour; after the incubation, the ELISA plate was removed, washed 3 times with PBST, and HRP-labeled murine monoclonal antibody OTI9A5 was added as a detection antibody, and incubated at 37℃for 1 hour. PBST was washed 5 times, TMB substrate was added, and color development was performed at 37℃for 10min. After removal, stop solution was added and OD450 readings were measured on an microplate reader. The optimal rabbit monoclonal antibody pair is selected according to the OD value of the sample and the background value of the negative control, and the pairing screening result is shown in Table 1.
Table 1 results of screening of antibody pairing experiments
It can be seen that the antibody OTIR5D9 referred to in this application was the best coated antibody, and murine monoclonal antibody OTI9A5 was the best detection antibody.
Example 3 analysis of the variable region Gene and amino acid sequence of the rabbit monoclonal antibody OTIR5D9 recombinant plasmid of the OTIR5D9 antibody was used as a DNA template, and the light chain variable region and heavy chain variable region sequencing primers were designed based on the 5' -end vector sequences of the light chain and heavy chain on the template, and sequenced using a sequencer ABI 3730. The nucleotide sequence of the variable region of the light chain and the heavy chain of the rabbit monoclonal antibody OTIR5D9 is obtained through sequencing.
The nucleotide sequences of the light chain variable region and the heavy chain variable region are respectively subjected to sequencing result data analysis by using IMGT/V-QUEST analysis software on http:// www.imgt.org through the Internet, the amino acid sequence of the light chain variable region of the rabbit monoclonal antibody OTIR5D9 is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 2. VL is 110 amino acids in total, the number of amino acids in 4 domains of FR is 26, 17, 36 and 10 respectively, the number of amino acids in3 domains of LCDR is 8, 3 and 10 respectively, and the regions of LCDR1, LCDR2 and LCDR3 are 27aa-34aa,52aa-54aa and 91aa-100aa respectively, and the amino acid sequences thereof are: QNVYGNNR (SEQ ID No. 3), QAS (SEQ ID No. 4), AGWASDYTHA (SEQ ID No. 5); the total length of VH is 112 amino acids, the numbers of 4 structural domain amino acids of FR are 24, 17, 37 and 11 respectively, the numbers of 3 structural domain amino acids of HCDR are 8, 7 and 8 respectively, HCDR1, HCDR2 and HCDR3 are 25aa-32aa,50aa-56aa and 94aa-101aa respectively, and the amino acid sequences are GFSLSNDW (SEQ ID NO. 6), ISHSGTT (SEQ ID NO. 7) and ARHIGGDD (SEQ ID NO. 8) respectively.
Example 4 anti-human acetylated tau281 rabbit monoclonal antibody OTIR5D9 is used for preparing double antibody sandwich ELISA detection kit based on ELISA double antibody sandwich principle detection technology, and human acetylated tau281 detection kit is prepared for clinical auxiliary diagnosis of diseases related to human acetylated tau 281.
1. Kit composition
1. Laths coated with OTIR5D9 antibodies: diluting the antibody to 1 mug/ml with PBS buffer, coating onto a microplate, incubating overnight at 4 ℃ with 100 mug/well, washing 3 times with PBST, and spin-drying; blocking with PBS containing 1% BSA, 5% sucrose and 0.05% proclin300, reacting at 37deg.C for 2 hr, discarding the blocking solution in the hole, and drying; and (3) placing the coating plate in a baking oven at 37 ℃ for 2 hours to finish coating, sealing by an aluminum foil bag, and storing at 4 ℃ for standby.
2. Reagent preparation
2.1 preparation of enzyme conjugate the simple sodium periodate method is adopted to mark anti-human non-phosphorylated Tau protein murine monoclonal antibody OTI9A5, the working concentration is titrated to prepare 1:20 concentrated solution, the diluted solution is PBS containing 1% BSA, 5% glycerol and 0.05% Proclin300, and the solution is filtered and sterilized.
2.2 washing buffer was conventional PBST at pH7.4 containing 0.05% Proclin300 and was formulated as a 20-fold concentrate.
2.3 substrate solution (color developing solution) of enzyme one-component TMB (purchased from market).
2.4 sample dilutions contained 1% BSA, 0.05% Proclin300 in PBS, and were sterilized by filtration.
2.5 stop solution 10ml HCl (36-38%) was added to 110ml distilled water and the mixing was slowly performed to prepare 1N HCl.
2.6 Standard full Length human acetylated tau281 protein, diluted to 20 μg/ml with PBS containing 1% BSA, 5% sucrose, 10% glycerol, 0.05% Proclin300, filtered, sterilized and aseptically packaged.
2. Detecting the operation key points
1. In order to ensure the accuracy of the detection result, it is suggested that both the standard and the sample are provided with double-hole measurement. Standard curves are needed for each detection.
2. If the content of the substance to be detected in the sample is too high, the sample is diluted by the sample diluent to ensure that the sample accords with the detection range of the kit, and finally, the sample is multiplied by the corresponding dilution multiple during calculation.
3. Sample adding: during sample addition, a disposable clean suction head is required to be used, so that cross contamination is avoided. The sample should be added as slowly as possible to avoid foaming, and the sample is added at the bottom of the ELISA plate hole without adding the sample along the hole wall.
4. Incubation: in order to prevent sample evaporation or contamination, the ELISA plate must be covered and attached during incubation, and the ELISA plate should be prevented from being in a dry state during the experiment. During the incubation process, whether the temperature of the incubator is constant at 37 ℃ or not should be observed at any time, and the temperature should be adjusted in time. During the incubation, the incubator is not easily opened too many times to avoid affecting the temperature balance.
5. Washing: the washing process is very important, and insufficient washing is prone to false positives.
6. Color development: in order to ensure the accuracy of the experimental result, the stop solution should be added as soon as possible after the substrate reaction time. The color development can be observed at intervals after the substrate solution is added to control the reaction time (e.g., at intervals of 10 minutes). When the front 3-4 holes of the standard product are visible to naked eyes and have obvious gradient blue, and the color development of the rear 3-4 holes is not obvious, stopping solution can be added to stop the reaction, and the blue color immediately turns yellow. The order of addition of the stop solution should be as similar as possible to the order of addition of the substrate solution.
7. The substrate solution should be bluish or colorless and must be discarded if the color becomes severely darkened. The substrate solution is easy to be polluted and is required to be preserved properly in dark place.
3. Determination of standard human acetylated tau281 protein different dilution standard curve
The prepared double-antibody sandwich ELISA detection kit for detecting the human acetylated tau281 protein is taken out from a refrigerator at 4 ℃ and balanced to the room temperature. The standard was diluted from 20. Mu.g/ml to 10000pg/ml with PBS to prepare 9 series of concentration standard substances of 0, 78, 156, 313, 625, 1250, 2500, 5000, 10000pg/ml, 100. Mu.l of the standard substance was added to each well for incubation according to the above detection method, then the liquid was discarded, an HRP-labeled detection antibody working solution was added for incubation, the liquid in the well was discarded, a substrate solution was added to each well after spin-drying, a stop solution was added to each well after development in the absence of light, and the optical density OD value of each well was measured sequentially at 450nm with an enzyme-labeled instrument within 5 minutes after termination of the reaction to make a standard curve, and the results are shown in Table 2.
Table 2 double antibody sandwich ELISA method for detecting human acetylated tau281 standard substance
A human acetylated tau281 detection standard curve was made according to table 2, see figure 3. R of standard curve 2 =0.9904, linear detection range 0-10000pg/mL, deriving the sample concentration calculation formula: y=0.0002x+0.1459, the detection sensitivity is less than 78pg/ml.
In summary, the anti-human acetylated tau281 rabbit monoclonal antibody is applied to double-antibody sandwich ELISA for detecting phosphorylated tau281 standard antigen, and the detection sensitivity is less than 78pg/ml.
The present embodiment is merely illustrative of the present application and is not intended to be limiting, and those skilled in the art, after having read the present specification, may make modifications to the present embodiment without creative contribution as required, but is protected by patent laws within the scope of the claims of the present application.
Claims (10)
1. A rabbit monoclonal antibody against human acetylated tau281, comprising a light chain variable region and a heavy chain variable region, the light chain variable region comprising LCDR1-3, the LCDR1 comprising an amino acid sequence as shown in SEQ ID No.3, the LCDR2 comprising an amino acid sequence as shown in SEQ ID No.4, the LCDR3 comprising an amino acid sequence as shown in SEQ ID No. 5; the heavy chain variable region comprises HCDR1-3, wherein HCDR1 comprises an amino acid sequence shown as SEQ ID NO.6, HCDR2 comprises an amino acid sequence shown as SEQ ID NO.7, and HCDR3 comprises an amino acid sequence shown as SEQ ID NO. 8.
2. The rabbit monoclonal antibody of claim 1, wherein the light chain variable region comprises an amino acid sequence set forth in SEQ ID No.1 and the heavy chain variable region comprises an amino acid sequence set forth in SEQ ID No. 2.
3. An isolated polynucleotide encoding the rabbit monoclonal antibody of any one of claims 1-2.
4. A recombinant expression vector comprising the polynucleotide of claim 3.
5. A host cell comprising the recombinant expression vector of claim 4, wherein the host cell is a prokaryotic cell or a eukaryotic cell.
6. An immunoassay product of human acetylated tau281, comprising the rabbit monoclonal antibody of claim 1 or 2.
7. The immunoassay product of claim 6, wherein the immunoassay product is a test kit, chip or test strip.
8. Use of a rabbit monoclonal antibody according to claim 1 or 2 for the preparation of an immunoassay product for detecting human acetylated tau281 protein.
9. The use according to claim 8, wherein the immunodetection product is a detection kit, a chip or a detection strip.
10. The use according to claim 9, wherein the detection kit is a double antibody sandwich ELISA detection kit or a chemiluminescent immunoassay kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311626889.XA CN117624354B (en) | 2023-11-30 | 2023-11-30 | Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311626889.XA CN117624354B (en) | 2023-11-30 | 2023-11-30 | Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117624354A true CN117624354A (en) | 2024-03-01 |
| CN117624354B CN117624354B (en) | 2024-07-12 |
Family
ID=90020967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311626889.XA Active CN117624354B (en) | 2023-11-30 | 2023-11-30 | Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117624354B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117624355A (en) * | 2023-11-30 | 2024-03-01 | 无锡傲锐东源生物科技有限公司 | Anti-human acetylated tau274 rabbit monoclonal antibody and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104185640A (en) * | 2011-09-19 | 2014-12-03 | 阿克松神经系统科学公司 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| CN113817062A (en) * | 2021-07-26 | 2021-12-21 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human hydroxysteroid 17-beta dehydrogenase 13(HSD17B13) and application thereof |
| CN115724967A (en) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | Monoclonal antibody for identifying Tau protein N-terminal region and application thereof |
| CN116041502A (en) * | 2022-09-21 | 2023-05-02 | 天津鸿宇泰生物科技有限公司 | Monoclonal antibody for recognizing phosphorylation of Tau protein pT181 and application thereof |
| CN116375856A (en) * | 2023-03-27 | 2023-07-04 | 陕西师范大学 | anti-Tau protein monoclonal antibody 1A5-47H7, product based on same and application |
-
2023
- 2023-11-30 CN CN202311626889.XA patent/CN117624354B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104185640A (en) * | 2011-09-19 | 2014-12-03 | 阿克松神经系统科学公司 | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
| CN113817062A (en) * | 2021-07-26 | 2021-12-21 | 无锡傲锐东源生物科技有限公司 | Rabbit monoclonal antibody against human hydroxysteroid 17-beta dehydrogenase 13(HSD17B13) and application thereof |
| CN115724967A (en) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | Monoclonal antibody for identifying Tau protein N-terminal region and application thereof |
| CN116041502A (en) * | 2022-09-21 | 2023-05-02 | 天津鸿宇泰生物科技有限公司 | Monoclonal antibody for recognizing phosphorylation of Tau protein pT181 and application thereof |
| CN116375856A (en) * | 2023-03-27 | 2023-07-04 | 陕西师范大学 | anti-Tau protein monoclonal antibody 1A5-47H7, product based on same and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117624355A (en) * | 2023-11-30 | 2024-03-01 | 无锡傲锐东源生物科技有限公司 | Anti-human acetylated tau274 rabbit monoclonal antibody and application thereof |
| CN117624355B (en) * | 2023-11-30 | 2024-05-14 | 无锡傲锐东源生物科技有限公司 | Anti-human acetylated tau274 rabbit monoclonal antibody and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117624354B (en) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112250763B (en) | Antibody targeting SARS-CoV-2 coronavirus and its diagnosis and detection use | |
| Kosik et al. | Epitopes that span the tau molecule are shared with paired helical filaments | |
| CN114181908B (en) | Anti-human S100B protein mouse monoclonal antibody and application thereof | |
| CN117624354B (en) | Anti-human acetylated tau281 rabbit monoclonal antibody and application thereof | |
| CN113683688B (en) | anti-HIV type I P24 antigen (HIV-1P 24) rabbit monoclonal antibody and application thereof | |
| WO2007021255A1 (en) | Antibodies to alpha-synuclein | |
| WO2005047860A2 (en) | Antibodies to alpha-synuclein | |
| CN117624351B (en) | Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof | |
| CN113817062B (en) | Anti-human hydroxysteroid 17-beta dehydrogenase 13 (HSD 17B 13) rabbit monoclonal antibody and application thereof | |
| CN110938140B (en) | Monoclonal antibody of Coxsackie virus A10 type solid virus and application thereof | |
| CN106939034B (en) | Methods and kits for identifying HEV genotypes infected by a subject | |
| CN117624367A (en) | Anti-human CD141 protein rabbit monoclonal antibody and application thereof | |
| CN117624355B (en) | Anti-human acetylated tau274 rabbit monoclonal antibody and application thereof | |
| CN113956355B (en) | Anti-human Brain Natriuretic Peptide (BNP) rabbit monoclonal antibody and application thereof | |
| CN117624350B (en) | Anti-human phosphorylated tau217 rabbit monoclonal antibody and application thereof | |
| KR20120132227A (en) | Monoclonal antibody for detecting multiple type Foot and Mouth Disease Virus and method for detecting Foot and Mouth Disease Virus using the same | |
| US11307202B1 (en) | Antibody binding detection method for detecting MERS-CoV | |
| KR102163242B1 (en) | Monoclonal antibody against immunoglobulin m of rainbow trout and use thereof | |
| KR101919403B1 (en) | Recombinant protein and use thereof | |
| EP2187216B1 (en) | Novel liver cancer marker | |
| KR102163241B1 (en) | Monoclonal antibody against immunoglobulin m of rock bream and use thereof | |
| CN114456265B (en) | anti-HFABP monoclonal antibody and application thereof | |
| RU2754791C1 (en) | Mosaic recombinant polypeptide containing fragments of hepatitis e virus proteins of genotypes 1 and 3 in one polypeptide chain, intended for use in test systems used in the serodiagnosis of hepatitis e | |
| KR101287602B1 (en) | Antibody recognizing kidney type and respiratory type infectious bronchitis virus and use thereof | |
| CN118754983A (en) | Testosterone sandwich method rabbit monoclonal antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |